Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year
Gilead Sciences notched “fine” sales for the first quarter but the biopharma promised more to come.
Gilead reported sales of $6.6 billion, a 5% increase year-over-year, prompting Mizhuo analysts to write that the quarter “generally looks fine” on Thursday afternoon.
Executives emphasized seladelpar, a rare liver disease candidate that was picked up in its $4.3 billion CymaBay acquisition and has an August FDA decision date, in its Q1 earnings call Thursday. The potential primary biliary cholangitis treatment also is expected to get a decision in Europe in the first quarter of 2025.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
